Receptor Activator for Nuclear Factor κ B Ligand (RANKL)

Receptor activator for nuclear factor κ B ligand (RANKL) is a member of the tumor necrosis factor (TNF) cytokine superfamily. It plays a central role in bone metabolism, immune regulation, and has implications in cancer biology. RANKL is primarily produced by osteoblastic lineage cells and activated T cells. It exists as a cell-bound form and a secreted form. RANKL's primary receptor is RANK, expressed on osteoclast precursors, mature osteoclasts, activated T cells, and myeloid-derived dendritic cells. Osteoprotegerin (OPG) acts as a decoy receptor, binding to RANKL and preventing its interaction with RANK. RANKL is essential for osteoclast differentiation, activation, survival, and bone resorption. It is also involved in dendritic cell maturation and T cell-dependent immune responses. In cancer, RANKL can promote tumor growth and immune evasion. Upon binding to its receptor, key downstream pathways include NF-kappaB, JNK, and Akt/PKB, regulating gene transcription involved in survival, apoptosis, and differentiation.

Inhibition of RANKL binding to RANK, thereby preventing osteoclast formation, activation, and survival; modulating immune responses; blocking tumor growth and immune evasion.